Clinical usefulness of international normalized ratio calibration of prothrombin time in patients with chronic liver disease

International Journal of Hematology

Volumn 102, Issue 2, 2015, Pages 163-169

  Lee, Jun Hyung ^a   Kweon, Oh Joo ^a   Lee, Mi Kyung ^a   Lee, Hyun Woong ^a   Kim, Hyung Joon ^a   Kim, Hye Ryoun ^a  

^a Chung Ang University College of Medicine   (South Korea)

Author keywords

Calibration; International normalized ratio; Liver cirrhosis; Prothrombin time; Standardization

Indexed keywords

ALBUMIN; ANTICOAGULANT AGENT; BILIRUBIN; CREATININE; RECOMBINANT THROMBOPLASTIN; THROMBOPLASTIN;

ADULT; ALBUMIN BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CALIBRATION; CHILD PUGH SCORE; CHRONIC LIVER DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; END STAGE LIVER DISEASE; FEMALE; HEMATOLOGICAL PROCEDURE; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTERNATIONAL SENSITIVITY INDEX; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; PROTHROMBIN TIME; AGED; BLOOD; CHRONIC DISEASE; LIVER DISEASES; MIDDLE AGED; PROCEDURES; REFERENCE VALUE; STANDARDS;

AGED; CHRONIC DISEASE; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LIVER CIRRHOSIS; LIVER DISEASES; MALE; MIDDLE AGED; PROTHROMBIN TIME; REFERENCE VALUES; THROMBOPLASTIN;

EID: 84938958609     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-015-1820-2     Document Type: Article

References (19)

1. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–9.
2. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864–71. doi:10.1053/he.2000.5852.
3. Tripodi A, Chantarangkul V, Primignani M, Fabris F, Dell’Era A, Sei C, Mannucci PM. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology. 2007;46(2):520–7. doi:10.1002/hep.21732.
4. Bellest L, Eschwege V, Poupon R, Chazouilleres O, Robert A. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology. 2007;46(2):528–34. doi:10.1002/hep.21680.
5. Procedures for validation of INR and local calibration of PT/INR systems; approved guideline (Document H54-A). Wayne, Pennsylvania, Clinical and Laboratory Standards Institute; 2005;25(23).
6. van den Besselaar AM, Barrowcliffe TW, Houbouyan-Reveillard LL, Jespersen J, Johnston M, Poller L. Tripodi. Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determination. J Thromb Haemost. 2004;2(11):1946–53. doi:10.1111/j.1538-7836.2004.00970.x.
7. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays; Approved Guideline, 5th ed. CLSI Document H21-A5., vol 28. Wayne, Pennsylvania, Clinical and Laboratory Standards Institute; 2008.
8. World Health Organization Expert Committee on Biological Standardization. Guidelines for thromboplastins and plasma used to control anticoagulant therapy. WHO Tech Rep Ser. 1999;889:64–93.
9. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007;45(3):797–805. doi:10.1002/hep.21563.
10. Deitcher SR. Interpretation of the international normalised ratio in patients with liver disease. Lancet. 2002;359(9300):47–8. doi:10.1016/s0140-6736(02)07282-3.
11. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147–56. doi:10.1056/NEJMra1011170.
12. Tripodi A, Primignani M, Lemma L, Chantarangkul V, Dell’Era A, Iannuzzi F, Aghemo A, Mannucci PM. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology. 2010;52(1):249–55. doi:10.1002/hep.23653.
13. Poller L, van den Besselaar AM, Jespersen J, Tripodi A, Houghton D. The European Concerted Action on Anticoagulation (ECAA): field studies of coagulometer effects on the ISI of ECAA thromboplastins. Thromb Haemost. 1998;80(4):615–23.
14. Denson KW, Reed SV, Haddon ME. Validity of the INR system for patients with liver impairment. Thromb Haemost. 1995;73(1):162.
15. Denson KW, Reed SV, Haddon ME, Woodhams B, Brucato C, Ruiz J. Comparative studies of rabbit and human recombinant tissue factor reagents. Thromb Res. 1999;94(4):255–61.
16. Coombes JM, Trotter JF. Development of the allocation system for deceased donor liver transplantation. Clin Med Res. 2005;3(2):87–92.
17. Feyssa E, Ortiz J, Grewal K, Azhar A, Parsikia A, Tufail K, Hashemi N, Brady P, Araya V. MELD score less than 15 predicts prolonged survival after transjugular intrahepatic portosystemic shunt for refractory ascites after liver transplantation. Transplantation. 2011;91(7):786–92. doi:10.1097/TP.0b013e31820e014e.
18. Poller L, van den Besselaar AM, Jespersen J, Tripodi A, Houghton D. Correction for lack of coincidence of normal and abnormal calibration slopes in ISI determination. Thromb Haemost. 1999;81(6):935–9.
19. Tripodi A, Chantarangkul V, Akkawat B, Clerici M, Mannucci PM. A partial factor V deficiency in anticoagulated lyophilized plasmas has been identified as a cause of the international normalized ratio discrepancy in the external quality assessment scheme. Thromb Res. 1995;78(4):283–92.